Max Robotics — Global Service Robot Directory + US Certification

About

Rick Hermsen is a leading researcher in the field of urologic oncology, with a primary focus on advancing prostate cancer imaging and staging. His work centers on the clinical application of PSMA-PET/CT, particularly in improving preoperative risk stratification and predicting patient outcomes. Hermsen’s major contributions include demonstrating that preoperative PSMA-PET/CT is a powerful predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection, a finding supported by 29 citations. He also conducted a landmark head-to-head comparison of 18F-PSMA-1007 PET/CT against multiparametric MRI, using whole-mount histopathology as the gold standard, which showed superior accuracy in localizing and staging primary prostate cancer (20 citations). Further, his research has validated PSMA-PET/CT through immunohistochemical and histopathological correlation, confirming its reliability for identifying intraprostatic lesions. Most recently, Hermsen has explored the prognostic value of PSMA-PET/CT-based local staging in predicting biochemical recurrence-free survival, suggesting it may outperform conventional imaging for risk stratification. His work is instrumental in refining surgical planning and postoperative monitoring, with cumulative citations exceeding 55, marking him as a key figure in precision oncology for prostate cancer.